APR 10, 2020 8:54 PM PDT

Cancer Therapy Drug Reverses Kidney Damage

WRITTEN BY: Nouran Amin

According to a study published in the journal Science Translational Medicine, a therapeutic previously used for cancer therapy has shown promising effects on reversing kidney damage in patients with systemic lupus erythematosus (SLE, or lupus).

Learn more about SLE:

"Kidney damage affects about half of the patients with lupus, sometimes leading to renal failure with a requirement for dialysis or transplantation," said Joe Craft, the Paul B. Beeson Professor of Medicine (rheumatology) and professor of immunobiology at Yale University. "Finding what causes that damage is extremely important."

SLE is an autoimmune disease caused by the individual’s immune cells attack their own tissues and kidneys can be particularly susceptible to the disease pathology resulting in lupus nephritis.

For lupus nephritis, a cell population referred to as ‘T-cells’ colonize kidney tissue triggering a decrease in oxygen and leading to tissue damage, potentially end-stage kidney disease. When researchers investigated the effects on infiltrating T-cells, they found that the T-cells express a marker known as hypoxia-inducible factor-1 (HIF-1) that is dependent on oxygen levels in the kidney. Activating HIF-1, results in the T-cells attacking the kidney tissues and furthering causing destruction of kidney function.

These findings allowed investigators to hypothesize that inhibiting HIF-1 function might increase oxygen levels and reduce the impact on kidneys. Thus, researchers used the HIF-1 blocking drug previously utilized in cancer therapy on mouse models of lupus.

"The findings suggest this therapy might be beneficial in lupus nephritis," Craft said. "Since this drug and others that block HIF-1 function have been used in humans with cancer, they could be used for treatment of patients with lupus."

Source: Science Daily

 

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
APR 15, 2020
Immunology
APR 15, 2020
Does COVID-19 Attack the Immune System like HIV?
Researchers from the US and China have found that COVID-19 can destroy T cells, a type of lymphocyte that plays a key ro ...
APR 23, 2020
Cancer
APR 23, 2020
Dual Inhibition from One Chemotherapy
Acute Myeloid Leukemia, or AML, is an aggressive blood cancer with a poor 5-year prognosis. The primary targets of chemo ...
APR 17, 2020
Drug Discovery & Development
APR 17, 2020
Overcoming Multi-Drug Resistance in Cancer
Resistance to chemotherapeutic use in caner patients is something that is inevitable. Continued resistance to these drug ...
MAY 02, 2020
Cancer
MAY 02, 2020
Tracking DNA Methylation as a Prognostic Marker
In the modern age of biological research, one of the tools that have become readily available in the ever-increasing dat ...
MAY 13, 2020
Drug Discovery & Development
MAY 13, 2020
FDA Fast Tracks Vaccine for COVID-19
Biopharmaceutical company, Moderna, has announced that the US Food and Drug Administration has approved its experimental ...
MAY 21, 2020
Cancer
MAY 21, 2020
A New Player in the Regulation of Cancer's Microenvironment
Breast cancer is one of the most common cancers in the world.  Triple-negative breast cancer (TNBC) is a sub-type o ...
Loading Comments...